BRAF and melanoma: The mutational status of metastatic lesions cannot easily be tested because melanoma metastasizes to subcutaneous and superficial lymph nodes, visceral areas, and deep lymph nodes; therefore, in such cases, whether BRAF/MEK inhibitors are suitable for patients with melanoma is unclear (7).